维普中文期刊产品整合服务

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab

查看全文 作　　者：Rachel Hui Fen Lim Bhaskar Gupta Peter [1]Simcock 高影响力作者 机构地区：[1]Royal Devon and Exeter NHS Foundation Trust, BarrackRoad, Exeter, EX2 5DW, United Kingdom高影响力机构 出　　处：《International Journal of Ophthalmology(English edition)》索引2017年第10卷第3期,共4页高影响力期刊 摘　　要：AIM:To report the change in visual acuity and central macular thickness(CMT)following treatment with intravitreal aflibercept injections in patients with neovascular agerelated macular degeneration(n AMD)with suboptimum response to ranibizumab.METHODS:This was a retrospective study. The inclusion criteria were patients with n AMD who responded poorly to ranibizumab. Patients then received either 3 consecutive aflibercept injections followed by pro re nata(PRN)treatment or PRN alone. Primary endpoints were mean change in bestcorrected visual acuity(BCVA)and CMT at 12 mo. Secondary endpoints were number of injections and adverse events.RESULTS:Forty-nine eyes from 49 patients met the inclusion criteria and completed 12-month follow up on aflibercept. Thirty-eight eyes received 3 consecutive aflibercept injections followed by PRN treatment and 11 eyes received PRN injections alone. At 12 mo,mean BCVA improved by one letters(log MAR 0.56±0.31 to 0.54±0.34)and mean CMT decreased from 303.9±82.1 to 259.2±108.3 μm.Four percent of eyes gained 15 letters or more,6% lost more than 15 letters and the remaining 90% had stable BCVA. The mean number of aflibercept injections was 6.There was one case of infectious endophthalmitis.CONCLUSION:Intravitreal aflibercept in patients with n AMD with a previous suboptimal response to ranibizumab resulted in an anatomical improvement in macular appearance at 12 mo without a corresponding improvement in visual acuity. 关 键 词：AFLIBERCEPT RANIBIZUMAB neovascular 年龄相关的有斑点的退化
相关文献

参考文献(20)

引证文献(3)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费